Accelerated Approval Does Not Accelerate ACIP Recommendation For Prevnar 13 In Adults
Pfizer still plans to launch Prevnar 13 for adults 50 and older absent an ACIP treatment recommendation, creating an interesting situation for physicians.
You may also be interested in...
New post-marketing commitment will look at conjugate pneumonia vaccine when given in patients 50 and older who have already received Merck’s polysaccharide vaccine.
Oncology Center of Excellence is reviewing a research report on fluorouracil, and will next look to update cisplatin's label, but eventually must convince the reference product sponsor to submit the changes.
With the pre-GDUFA backlog largely acted upon, the FDA expects ANDA approvals to decrease, but supplement actions to increase in FY 2020 and FY 2021.